

ARTIMPLANT INTERIM REPORT JANUARY – SEPTEMBER 2007



- Net revenue for the third quarter increased to SEK 2.6 million (0.9) and for the first nine months to SEK 11.2 million (3.9)*
- The net loss for the third quarter amounted to SEK 3.6 million (15.9) and for the first nine months to SEK 11.3 million (46.5)
- The net loss for the third quarter, excluding a non-recurring item, amounted to SEK 3.6 million (10.4) and for the first nine months to SEK 9.7 million (29.4)
- Earnings per share, including a non-recurring item, amounted to SEK -0.19 (-0.79)
- Artelon® Tissue Reinforcement was granted clearance in the USA to be marketed for all tendons of the rotator cuff and for four new indications
- Kauko Haapasaari has been employed as head of marketing
- More than 5,000 patients have been treated with Artelon® implants since the launch

EVENTS AFTER THE PERIOD-END

- Biomet's agreement for the rotator cuff application was renegotiated to non-exclusive status
- Biomet has been granted a global, non-exclusive right to market SportMesh™ for four new indications
- Artimplant's obligation to pay future royalties to the inventor of Artelon® was cleared for SEK 2.8 million

This information is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on November 9, 2007 at 8:45 am.

Artimplant will hold a telephone conference on this report on November 9, 2007 at 11 am. For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year



Artimplant

Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon[®], a biomaterial developed by the Company, satisfy clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for the treatment of osteoarthritis in the hands and feet, for shoulder and other soft tissue injuries as well as oral applications. All product development and production is carried on by Artimplant. The Company's products are marketed by established companies, mainly through global license agreements with Artimplant. The Company is developing its operations to secure long-term establishment via a number of market channels, including future establishment through in-house brands on a growing market.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in the Small Cap segment and in the healthcare sector.

Artimplant's mission

Artimplant's mission is to restore the health of patients by offering medical professionals degradable implants that help the body to heal.

Artimplant's vision

Artimplant's vision is to improve the quality of life for millions of people by helping their bodies to heal.

Financial results

Net sales for the third quarter amounted to SEK 2.6 million (0.9) and for the first nine months to SEK 11.2 million (3.9). A total of 89% of revenue for the first nine months derives from product sales with associated license revenues.

The operating loss for the third quarter was SEK 4.1 million (16.3) and for the first nine months it was SEK 13.0 million (47.7).

The net loss for the third quarter amounted to SEK 3.6 million (15.9) and for the first nine months to SEK 11.3 million (46.5). Excluding

non-recurring items, the net loss for the third quarter was SEK 3.6 million (10.4) and for the first nine months it amounted to SEK 9.7 million (29.4).


Non-recurring items refer to severance costs of SEK 1.6 million during the second quarter of 2007 and the impairment of product development costs brought forward by SEK 11.6 million during the second quarter of 2006 and by SEK 5.5 million during the third quarter of 2006. The net loss for the period has not been affected materially by exchange rate fluctuations. Earnings per share, including the non-recurring item, amounted to SEK -0.19 (-0.79).

Investments and cash position

Investments during the first nine months totaled SEK 1.0 million (1.8) with SEK 0.4 million (0.8) attributable to investments in intangible assets (patents). At the end of the period cash and cash equivalents amounted to SEK 55.7 million (77.7).

Sales of Artelon[®] products

Since the launch of Artelon[®] more than 5,000 patients have been treated with Artelon[®] implants. Sales of Artelon[®] Spacer to Small Bone Innovations' (SBI) customers increased during the first nine months to approximately 2,800 (1,700) units, of which approximately 700 (800) units were sold during the third quarter.



The negative sales trend leveled out during the third quarter. The measures implemented by SBI have begun to take affect. A new surgical procedure has been launched. It offers more stable fixation, which should ensure less postoperative pain. SBI's rapid market penetration means that more than 700 customers have purchased Artelon[®] Spacer. The majority have only carried



out a few operations and do not have the experience required to continuously ensure a positive clinical outcome. Artelon[®] CMC Spacer is a verified and successful form of treatment for thumb-base osteoarthritis. The clinical results are, however, entirely dependent on the patient belonging to the correct target group, that the surgical procedure is carried out correctly and that the postoperative rehabilitation process takes place so that the implant becomes attached.

A medical evaluation, based on two clinical studies and experience from more than 3,500 treated patients, has been conducted with support from Artimplant. The document summarizes the medical outcome and verifies that Artelon[®] is biocompatible and that Artelon[®] CMC Spacer is an effective method of treatment for thumb-base osteoarthritis.

At the American Association of Hand Surgeons' Annual Meeting, SBI ran two well-attended seminars on Artelon[®] CMC Spacer. When training its customers SBI now makes use of reference surgeons who have conducted up to 100 Spacer operations.

SBI's management is very clear about how strategically important Artelon[®] Spacer is to SBI and it confirms its intention to return to the previous level of sales growth.

During the third quarter SBI introduced Artelon[®] STT Spacer and Artelon[®] CMC Spacer Arthro for keyhole surgery on the American market. Both products were cleared by the FDA in June. Artimplant does not expect any large sales volumes for these products until SBI has conducted market studies among surgeons in the USA. SBI estimates that 10% of hand surgeons in the USA use arthroscopic surgery. As regards the market for osteoarthritis in the STT joint, Artimplant estimates that approximately 25% of the patients who are diagnosed with osteoarthritis in the CMC joint also have osteoarthritis in the STT joint.

Marketing of Artelon[®] Tissue Reinforcement (ATR) started during Q4 2006. The product has been cleared as reinforcement for soft tissue injuries. It is sold exclusively by Biomet Sports Medicine as SportMesh[™] for the rotator cuff application. In December 2006 a private equity

consortium made a bid for the Biomet Group and the takeover was concluded in September 2007 when Biomet also ceased trading on Nasdaq. The new owners have gradually begun to make their mark on operations during 2007. During the third quarter Artimplant and Biomet Sports Medicine discussed the conditions for expanded collaboration. The discussions are taking place in the light of Artimplant's extended FDA clearance for ATR and Biomet Sports Medicine's orientation with new owners. During the third quarter of 2007 sales remained on the same level as during the second quarter with approximately 150 units. Biomet has decided to start an important clinical post-market study in Belgium during Q4 2007. Clinical experience shows that ATR is easy to use and is less dependent on surgical procedure and rehabilitation than Artelon[®] CMC Spacer. The market for ATR is thus considered to be significantly larger than for Artelon[®] CMC Spacer.

During the third quarter Artimplant commenced marketing activities for ATR in Europe. The Company has, among other things, exhibited at a sports injuries congress. A consultancy agreement has been signed with Professor Lars Peterson, who together with Artimplant's new sales management team has commenced the build-up of European reference clinics with the aim of creating a scientific and commercial foundation for continued market penetration.

Medical experience of the patients who had been treated with ATR is positive in all applications that have been tested. However, published clinical data is required as sale support. Artimplant has decided to carry out its own studies.

Product development and approvals

In September, Artimplant was granted clearance to market ATR for new indications in the USA. Clearance offers the opportunity to sell the product on a considerably larger market than previously. Examples of new indications which can be marketed are reinforcement of all tendons in the shoulder rotator cuff, tendon injuries around the kneecap, biceps, quadriceps and in addition Achilles tendons. Previous clearance in the USA was limited to marketing of the product for a ligament in the shoulder rotator cuff

(Supraspinatus). Biomet thus has the opportunity to market SportMesh™ for rotator cuff injuries which was not possible previously.

During the second quarter Artimplant was granted clearance to market two new Spacer products in the USA, Artelon® STT Spacer and Artelon® CMC Spacer Arthro. The products were launched in the USA during the third quarter by SBI.

Artelon® Cosmetic for the augmentation of soft tissue in dental applications was granted ethical clearance in June for two post-market studies. The studies are being run by the Brånemark Clinic in Gothenburg and the Faculty of Odontology at Göteborg University.

Artimplant is developing a new design for Artelon® Bone Scaffold for bone augmentation in the upper jaw in conjunction with a sinus lift. Work is due to be completed during the fourth quarter.

Personnel

Kauko Haapasaari has been employed as head of marketing with effect from October 1. Haapasaari has extensive experience in marketing and sales, most recently as head of business development at Raisio Diagnostics.

As of September 30, 2007, Artimplant employed 24 people (31), of whom 12 are women and 12 are men.

Operative direction 2007

Artimplant's prioritized development projects during 2007 extend from the Company's three product concepts:

- Spacer (resurfacing): Commencement of the development of a number of new products within hand and foot surgery.
- Tissue Reinforcement (reinforcement): New sizes have been developed and FDA clearance for extended indication has been granted.
- Scaffold (replenish): Two post-market studies are proceeding according to plan to document Artelon® Cosmetic. A new Artelon® Bone Scaffold design is due to be completed during the fourth quarter.

There are numerous potential application areas for Artelon® with its unique property to help the body to heal. Not all can be exploited by Artimplant. In 2007, Artimplant plans to outlicense Artelon® for certain single application areas.

Parent Company

The majority of operations are run through the Parent Company, Artimplant AB. Artimplant USA, Inc. is the only subsidiary and is at present fully funded by the Parent Company. The Parent Company's revenue, investments and cash position during January-September 2007 correspond in all material respects to those of the Group. See summary of the Parent Company Income Statement and Balance Sheet on page 8.

Events after the period-end

In October, Artimplant cleared the obligation to pay future royalties to the holder of the basic patent for the biomaterial platform Artelon® in return for a lump sum payment of SEK 2.8 million. With effect from January 1, 2007 this will improve Artimplant's margin on license income from product sales by five percentage points. The payment will be charged to Artimplant's cash reserves and will be recorded as a patent investment during the fourth quarter of 2007.

After the period-end Biomet was granted a non-exclusive right to sell ATR for the new applications which were granted clearance by the FDA in September 2007. This gives Biomet the opportunity to address a much larger market, which is expected to increase their sales of SportMesh™ considerably. Existing agreements for the rotator cuff application have been renegotiated to non-exclusive status, which gives Artimplant the opportunity to exploit all product applications for ATR alongside Biomet.



Significant risks and uncertainty factors

The Company's significant risks and uncertainty factors are presented in the Board of Directors' Report in the most recent annual report. The Company considers that the presentation also applies to this report with the addition that as Artimplant sales in the USA increase so does the currency exchange risk. No derivatives were used during the period January-September 2007.

Accounting principles

Artimplant applies IFRS. This interim report has been prepared in accordance with IAS 34 and the Swedish Annual Accounts Act.

As of 2007, the Company does not capitalize product development costs, since difficulty predicting future revenue streams is part of the nature of the business.

During 2006, Artimplant developed its production facilities to meet the increased demand for Artelon® products. As of 2007, the cost of goods and services sold includes a larger share of the

fixed cost of the production facility in addition to variable production costs.

Forthcoming reports

Annual Report..... February 22, 2008
Three-monthly report..... May 6, 2008
Six-monthly report..... August 7, 2008
Nine-monthly report..... November 11, 2008

Financial reports are available on the Company's website www.artimplant.com and are also distributed to the media. For information regarding the business model, technology and products, see Artimplant's Annual Report 2006, which is available on the Company's website.

For further information please contact

Hans Rosén, Chief Executive Officer
Tel + 46 31 746 56 44, +46 708 583 470
hans.rosen@artimplant.com

Lars-Johan Cederbrant, Chief Financial Officer
Tel. +46 31 746 56 54, +46 703 016 854
lars-johan.cederbrant@artimplant.com

CONSOLIDATED INCOME STATEMENTS

Amounts in SEK thousand	Jul-Sep	Jan-Sep	Jul-Sep	Jan-Sep	Jan-Dec
	2007	2007	2006	2006	2006
Net sales	2,560	11,233	878	3,891	5,536
Cost of goods and services sold*	-298	-2,126	-106	-235	-616
Gross profit/loss	2,262	9,107	772	3,656	4,920
Research and development costs (1,2)	-4,140	-11,691	-11,636	-37,232	-43,177
Selling costs	-1,319	-7,067	-3,303	-8,929	-12,090
Administration costs	-949	-3,318	-2,168	-5,209	-7,183
Operating loss	-4,146	-12,969	-16,335	-47,714	-57,530
Interest income and other financial income	531	1,684	484	1,358	1,841
Interest expenses and other financial expenses	-13	-63	-9	-171	-330
Net financial items	518	1,621	475	1,187	1,511
Loss after financial items	-3,628	-11,348	-15,860	-46,527	-56,019
Taxes	-	-	-	-	-
Loss for the period	-3,628	-11,348	-15,860	-46,527	-56,019

*) Thereof SEK 575 thousand in variable costs in Jan-Sep 2007

The income statements include depreciation on tangible fixed assets and amortization on intangible fixed assets as shown in the following table.

Amounts in SEK thousand	Jul-Sep	Jan-Sep	Jul-Sep	Jan-Sep	Jan-Dec
	2007	2007	2006	2006	2006
(1) Capitalized R&D cost*	546	1,638	6,056	20,690	21,236
(2) Patents	148	393	215	567	779
Machinery and equipment	177	492	194	467	669
Total depreciation	871	2,523	6,464	21,724	22,685

* Impairment of capitalized R&D costs of SEK 17,118 thousand is included in Jan-Sep 2006.

ALLOCATION OF NET SALES

Amounts in SEK thousand	Jul-Sep	Jan-Sep	Jul-Sep	Jan-Sep	Jan-Dec
	2007	2007	2006	2006	2006
Source of revenue					
Licensing of product applications	1,025	4,253	-	446	1,031
Product sales	1,474	5,669	878	2,184	3,273
Milestone payments for product development projects	60	1,310	-	1,261	1,231
	2,560	11,233	878	3,891	5,536
Geographic areas					
Scandinavia	119	611	164	559	717
USA	2,441	10,622	714	3,332	4,819
	2,560	11,233	878	3,891	5,536

CONSOLIDATED BALANCE SHEETS

Amounts in SEK thousand	9/30/2007	9/30/2006	12/31/2006
ASSETS			
Capitalized product development	5,555	7,568	7,193
Patents	924	1,226	1,131
Total intangible fixed assets	6,479	8,794	8,324
Machinery and equipment	2,029	1,856	1,890
Total tangible fixed assets	2,029	1,856	1,890
Stock and participation in subsidiaries*	-	1,707	-
Total financial fixed assets	-	1,707	-
Total fixed assets	8,508	12,357	10,214
Raw materials, semi-finished and finished goods	2,626	992	903
Total inventories, etc.	2,626	992	903
Accounts receivable	644	105	417
Other receivables	1,601	1,656	1,570
Prepaid expenses and accrued income	2,786	2,467	1,270
Total short-term receivables	5,031	4,227	3,256
Cash and bank accounts	55,668	77,670	68,704
Total current assets	63,325	82,889	72,863
TOTAL ASSETS	71,832	95,245	83,077

Amounts in SEK thousand	9/30/2007	9/30/2006	12/31/2006
SHAREHOLDERS' EQUITY & LIABILITIES			
Equity			
Share capital	5,924	5,924	5,924
Premium reserve	71,660	126,922	127,042
Total restricted equity	77,584	132,846	132,966
Retained earnings	-23	362	557
Translation difference	2	-	110
Loss for the period	-11,348	-46,527	-56,019
Total retained loss	-11,369	-46,165	-55,352
Total equity	66,215	86,681	77,614
Provisions	117	343	353
Accounts payable	991	2,053	1,212
Liabilities, subsidiaries*	-	1,822	-
Other current liabilities	1,518	591	951
Accrued expenses and prepaid income	2,991	3,755	2,947
Total current liabilities	5,500	8,221	5,110
TOTAL SHAREHOLDERS' EQUITY & LIABILITIES	71,832	95,245	83,077

* Only for dormant companies in 2006, not Artimplant USA

CHANGES IN SHAREHOLDERS' EQUITY DURING THE PERIOD

Amounts in SEK thousand	Jan-Sep 2007	Jan-Sep 2006	Jan-Dec 2006
Equity at the beginning of the period	77,614	132,846	132,966
Benefit employee stock option (IFRS2)	-335	362	460
Regained VAT from share issue 2000	329	-	97
Translation difference	-45	-	110
Loss for the period	-11,348	-46,527	-56,019
Equity at the period-end	66,215	86,681	77,614

CONSOLIDATED CASH FLOW ANALYSES

Amounts in SEK thousand	Jan-Sep 2007	Jan-Sep 2006	Jan-Dec 2006
Operating activities			
Net loss after financial items	-11,348	-46,527	-56,019
Adjustment for items not effecting cash flow	2,399	22,186	23,477
Cash flow from operating activities before changes in working capital	-8,949	-24,341	-32,542
Cash flow from changes in working capital			
Changes in inventories	-1,723	-49	41
Changes in receivables	-1,775	-1,654	-684
Changes in liabilities	390	1,296	-5
Cash flow from operating activities	-12,057	-24,749	-33,190
Investment activities			
Acquisition of intangible fixed assets	-413	-838	-1,126
Acquisition of tangible fixed assets	-566	-929	-1,165
Cash flow from investment activities	-978	-1,767	-2,292
Financing activities			
Share issue	-	-	-
Cash flow from financing activities	-	-	-
Cash flow for the period	-13,036	-26,515	-35,482
Liquid funds at beginning of period	68,704	104,186	104,186
Liquid funds at the period-end	55,668	77,670	68,704

KEY RATIOS

	Jul-Sep 2007	Jan-Sep 2007	Jul-Sep 2006	Jan-Sep 2006	Jan-Dec 2006
Earnings per share, SEK	-0.06	-0.19	-0.27	-0.79	-0.95
Earnings per share after full dilution, SEK	-0.06	-0.19	-0.27	-0.79	-0.95
Equity per share, SEK	1.12	1.12	1.46	1.46	1.31
Equity per share after full dilution, SEK	1.12	1.12	1.46	1.46	1.31
No. of shares at the period-end	59,244,790	59,244,790	59,244,790	59,244,790	59,244,790
Average no. of shares	59,244,790	59,244,790	59,244,790	59,244,790	59,244,790
No. of shares after full dilution	60,446,582	60,446,582	60,997,792	60,997,792	60,348,628
Yield on equity, %	neg	neg	neg	neg	neg
Yield on capital employed, %	neg	neg	neg	neg	neg
Equity/assets ratio, %	92	92	91	91	93

PARENT COMPANY INCOME STATEMENTS

Amounts in SEK thousand	Jul-Sep 2007	Jan-Sep 2007	Jul-Sep 2006	Jan-Sep 2006	Jan-Dec 2006
Net sales	2,562	11,197	878	3,891	5,536
Cost of goods and services sold*	-298	-2,126	-106	-235	-616
Gross profit/loss	2,264	9,071	772	3,656	4,920
Research and development costs (1,2)	-4,140	-11,691	-11,636	-37,232	-42,146
Selling costs	-2,459	-7,197	-3,201	-7,473	-11,802
Administration costs	-1,002	-3,350	-2,168	-5,209	-7,011
Operating loss	-5,337	-13,167	-16,233	-46,258	-56,039
Net financial items	518	1,621	476	1,187	1,511
Loss after financial items	-4,819	-11,546	-15,757	-45,071	-54,528
Appropriations	-	-	-	-	76
Taxes	-	-	-	-	-
Loss for the period	-4,819	-11,546	-15,757	-45,071	-54,452

*) Thereof SEK 575 thousand in variable costs in Jan-Sep 2007

The income statements include depreciation on tangible fixed assets and amortization on intangible fixed assets as shown in the following table.

Amounts in SEK thousand	Jul-Sep 2007	Jan-Sep 2007	Jul-Sep 2006	Jan-Sep 2006	Jan-Dec 2006
(1) Capitalized R&D cost*	546	1,638	6,057	20,691	21,236
(2) Patents	148	393	215	567	779
Machinery and equipment	176	489	191	464	666
Total depreciation	870	2,520	6,463	21,722	22,681

* Impairment of capitalized R&D costs of SEK 17,118 thousand is included in Jan-Sep 2006.

PARENT COMPANY BALANCE SHEETS

Amounts in SEK thousand	9/30/2007	9/30/2006	12/31/2006
ASSETS			
Total intangible fixed assets	6,479	8,794	8,324
Total tangible fixed assets	2,017	1,842	1,879
Stock and participation in subsidiaries*	10	1,717	10
Total fixed assets	8,506	12,354	10,213
Total inventories, etc.	2,626	992	903
Accounts receivable	644	105	417
Receivables from affiliated companies	-	1,510	-
Other receivables	1,602	1,656	1,563
Prepaid expenses and accrued income	2,786	2,455	1,259
Total short-term receivables	5,032	5,725	3,239
Cash and bank accounts	55,440	77,537	68,628
Total current assets	63,098	84,254	72,770
TOTAL ASSETS	71,603	96,608	82,982

Amounts in SEK thousand	9/30/2007	9/30/2006	12/31/2006
SHAREHOLDERS' EQUITY & LIABILITIES			
Total equity	66,032	88,138	77,583
Provisions	117	343	353
Accounts payable	989	2,031	1,196
Liabilities, subsidiaries*	907	1,822	-
Other current liabilities	1,474	1,374	903
Accrued expenses and prepaid income	2,084	2,900	2,947
Total current liabilities	5,454	8,127	5,046
TOTAL SHAREHOLDERS' EQUITY & LIABILITIES	71,603	96,608	82,982

* Only for dormant companies in 2006, not Artimplant USA



The Board of Directors and the CEO certify that this Nine-monthly Report provides a true and fair overview of the Company's and the Group's operations, financial position and results and presents the material risks and uncertainty factors facing the Company and the companies which form part of the Group.

Gothenburg, November 9, 2007
Artimplant AB (publ)

Ingemar Kihlström
Chairman of the Board

Hans Rosén
President

Rickard Söderberg
Board Member

Lennart Ribohn
Board Member

Wenche Rolfsen Sandsborg
Board Member

Anna Malm Bernsten
Board Member

This report has not been reviewed by the Company's auditors.

History

1986 – 1996 – A medical need is identified and the development of a new biomaterial commences. During subsequent years material, product and production development takes place and the technology is verified through preclinical trials.

1997 - The Company acquires a Swedish patent for Artelon[®] hydrolyzable fiber polymers for use in temporary implants. The Company is floated on the Stockholm Stock Exchange. The first cruciate ligament (ACL) operations on human patients using implants from Artimplant are carried out within the framework of a pilot study.

1998 - The Company acquires Gothenburg Medical Center, a clinic specializing in sports-related injuries.

1999 - Pilot studies in the treatment of damaged thumb ligament and thumb base osteoarthritis are initiated. Artimplant's first multicenter trial in ACL reconstruction begins. Artimplant begins cooperation with Mölnlycke Health Care AB in the field of wound care.

2000 - The first multicenter trial in ACL reconstruction is concluded. The second multicenter ACL reconstruction trial begins. Artimplant's Artelon[®] patent is approved in the USA and Europe. The marketing organization is expanded.

2001 - Artimplant's quality assurance system is certified by Lloyds Register Quality Assurance. Artimplant's first product, the Artelon[®] Augmentation Device ACL is granted CE-certification and can now be marketed in Europe. The task of building up the Company's own marketing and sales organization ceased during the autumn. Products and material technology will be commercialized through the granting of licenses to leading companies with a global presence.

2002 - Agreement on wound care signed with Mölnlycke Health Care AB. An extensive restructuring program is commenced to reduce the Company's cost base.

2003 – The Company signs an agreement with Atlantech for sales in the UK of its Artelon[®] Augmentation Device ACL. Artimplant's Artelon[®] CMC Spacer for treating thumb base osteoarthritis receives clearance for marketing in Europe. Artelon[®] Surgical Suture is given clearance by the FDA for sales on the American market. The subsidiary Gothenburg Medical Center is sold.

2004 - Artelon[®] CMC Spacer receives clearance for marketing from the FDA for sales on the US market. Licensing agreements signed with Small Bone Innovations. A licensing agreement is signed with Biomet Inc. for the production of SportMesh[™]. Cooperation with Atlantech for the sale of Artelon[®] Augmentation Device ACL is concluded. Cooperation between Artimplant and Mölnlycke Health Care within wound care is concluded.

2005 - Four new licensing and development agreements are signed with Small Bone Innovations. A distribution agreement for Artelon[®] Surgical Suture in North America is signed with ArthroCare. Artelon[®] implant for reinforcing rotator cuffs is cleared for marketing in Europe. Office opened in the United States.

2006 - The Company receives clearance for marketing by the FDA for the sale of the SportMesh[™] rotator cuff implant in the USA. Four new Spacer products for the treatment of osteoarthritis in the hand and foot are granted clearance for marketing in Europe. The product Artelon[®] Augmentation Device ACL is discontinued. The sale of Artelon[®] CMC Spacer to end-customers increases by over 600% compared with 2005. Over 3,000 patients have been given an Artelon[®] implant at 500 clinics.